HAE Stock Analysis: Haemonetics | NYSE

Plasma Collection, Hemostasis Analysis, Vascular Closure, Surgical Guidewires

Total Rating 71

Safety 80

Buy Signal 1.40

Medical Devices
Industry Rotation: -2.1

Market Cap: 4.76B
Avg Turnover: 56.2M

Risk 3d forecast

Volatility60.6%

VaR 5^th Pctl9.15%

VaR vs Median-6.62%

Reward TTM

Sharpe Ratio1.81

Rel. Str. IBD97.7

Rel. Str. Peer Group97.7

Character TTM

Beta0.155

Beta Downside-0.124

Hurst Exponent0.558

Drawdowns 3y

Max DD51.04%

CAGR/Max DD0.21

CAGR/Mean DD0.49

EPS (Earnings per Share)

EPS CAGR: 12.91%
EPS Trend: 98.4%

Last SUE: 1.38
Qual. Beats: 1

Revenue

Rev. CAGR: 1.95%
Rev. Trend: 58.1%

Last SUE: 1.54
Qual. Beats: 2

Warnings

Overextended 3d

Tailwinds

Rs Leader

Idiosyncratic Leader

Ep Pivot

Seasonality 11.7 years of data

Jan -3.3% 44

Feb -1.8% 11

Mar +1.1% 10

Apr +0.9% 8

May -1.0% 5

Jun +0.6% 7

Jul +3.1% 56

Aug +4.3% 30

Sep -2.1% 15

Oct -3.7% 15

Nov +7.0% 12

Dec -1.7% 14

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: HAE Haemonetics

Haemonetics Corporation (NYSE: HAE) is a Boston-based medical technology company founded in 1971 that operates through three business segments: Plasma, Blood Center, and Hospital. Within its Plasma segment, the company supplies automated plasmapheresis systems (NexSys PCS) and donor management software (NexLynk DMS, Donor360) that enable plasma collection operators to manage donors, operations, and supply chains. Source plasma collected with such systems is a key raw material used by fractionators to produce therapies for immune deficiencies, bleeding disorders, and other rare conditions.

The Hospital segment spans a diversified product portfolio across multiple clinical specialties. In electrophysiology and structural heart, Haemonetics offers the SavvyWire sensor-guided guidewire for transcatheter aortic valve replacement (TAVR) procedures and the OptoWire pressure guidewire for measuring fractional flow reserve (FFR) and diastolic pressure ratio. In surgical and critical care settings, the companys TEG 6s is a cartridge-based viscoelastic hemostasis analyzer paired with TEG Manager software that connects analyzers hospital-wide and provides clinicians remote access to patient test results used to guide transfusion decisions.

Additional Hospital offerings include the Cell Saver Elite+ autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, and obstetric/gynecological surgeries, as well as the VASCADE family of catheter-based vascular closure devices that use collagen to induce clotting at the arterial puncture site. The company also provides transfusion management solutions and fiber optic sensor technology used in both medical devices and industrial applications. Haemonetics sells its products through a combination of a direct sales force and independent distributors, serving customers globally.

Headlines to Watch Out For

Plasma segment growth driven by NexSys PCS adoption among collectors
Hospital segment margins pressured by VASCADE and TEG competition
Blood Center demand stable as U.S. plasma supply tightens
TAVR guidewire SavvyWire sales accelerate with structural heart procedure volumes

Piotroski VR-10 (Strict) 6.5

Net Income: 96.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 4.63 > 1.0
NWC/Revenue: 40.50% < 20% (prev 28.36%; Δ 12.14% < -1%)
CFO/TA 0.14 > 3% & CFO 328.1m > Net Income 96.3m
Net Debt (958.0m) to EBITDA (261.2m): 3.67 < 3
Current Ratio: 3.08 > 1.5 & < 3
Outstanding Shares: last quarter (45.7m) vs 12m ago -5.48% < -2%
Gross Margin: 57.38% > 18% (prev 56.83%; Δ 0.56% > 0.5%)
Asset Turnover: 56.01% > 50% (prev 54.67%; Δ 1.34% > 0%)
Interest Coverage Ratio: 4.94 > 6 (EBIT TTM 151.1m / Interest Expense TTM 30.6m)

Altman Z'' 2.94

A: 0.23 (Total Current Assets 810.8m - Total Current Liabilities 263.2m) / Total Assets 2.37b
B: 0.13 (Retained Earnings 311.5m / Total Assets 2.37b)
C: 0.06 (EBIT TTM 151.1m / Avg Total Assets 2.41b)
D: 0.55 (Book Value of Equity 837.1m / Total Liabilities 1.53b)
Altman-Z'' = 2.94 = A

Beneish M -2.96

DSRI: 1.07 (Receivables 216.1m/200.8m, Revenue 1.35b/1.35b)
GMI: 0.99 (GM 56.83% / 57.38%)
AQI: 1.03 (AQ_t 0.53 / AQ_t-1 0.51)
SGI: 1.00 (Revenue 1.35b / 1.35b)
TATA: -0.10 (NI 96.3m - CFO 328.1m) / TA 2.37b)
Beneish M = -2.96 (Cap -4..+1) = A

What is the price of HAE shares?

As of October 09, 2026, the stock is trading at USD 119.47 with a total of 2,775,233 shares traded. Over the past week, the price has changed by +14.47%, over one month by +16.17%, over three months by +61.84% and over the past year by +134.35%.

Current recommended Stop Loss: 116.30 (which is 2.7% or 1.2 ATR below the current price).

Is HAE a buy, sell or hold?

Haemonetics has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy HAE.

StrongBuy: 5
Buy: 4
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the HAE price?

Analysts Target Price	111.5	-6.7%

Haemonetics (HAE) - Fundamental Data Overview as of 06 October 2026

Market Cap USD = 4.76b (4.76b USD * 1.0 USD.USD)
P/E Trailing = 50.5701
P/E Forward = 20.3252
P/S = 3.5226
P/B = 5.8057
P/EG = 1.6923
Revenue TTM = 1.35b USD
EBIT TTM = 151.1m USD
EBITDA TTM = 261.2m USD
Long Term Debt = 1.17b USD (from longTermDebt, last quarter)
Short Term Debt = 4.96m USD (from shortTermDebt, last quarter)
Debt = 1.18b USD (from shortLongTermDebtTotal, last quarter) + Leases 7.20m
Net Debt = 958.0m USD (calculated: Debt 1.18b - CCE 223.4m)
Enterprise Value = 5.72b USD (4.76b + Debt 1.18b - CCE 223.4m)
Interest Coverage Ratio = 4.94 (Ebit TTM 151.1m / Interest Expense TTM 30.6m)
EV/FCF = 19.64x (Enterprise Value 5.72b / FCF TTM 291.2m)
FCF Yield = 5.09% (FCF TTM 291.2m / Enterprise Value 5.72b)
FCF Margin = 21.54% (FCF TTM 291.2m / Revenue TTM 1.35b)
Net Margin = 7.12% (Net Income TTM 96.3m / Revenue TTM 1.35b)
Gross Margin = 57.38% ((Revenue TTM 1.35b - Cost of Revenue TTM 576.2m) / Revenue TTM)
Gross Margin QoQ = 59.76% (prev 57.23%)
Tobins Q-Ratio = 2.42 (Enterprise Value 5.72b / Total Assets 2.37b)
Interest Expense / Debt = 2.59% (Interest Expense 30.6m / Debt 1.18b)
Taxrate = 26.18% (34.1m / 130.4m)
NOPAT = 111.6m (EBIT 151.1m * (1 - 26.18%))
Current Ratio = 3.08 (Total Current Assets 810.8m / Total Current Liabilities 263.2m)
Debt / Equity = 1.41 (Debt 1.18b / totalStockholderEquity, last quarter 837.1m)
Debt / EBITDA = 3.67 (Net Debt 958.0m / EBITDA 261.2m)
Debt / FCF = 3.29 (Net Debt 958.0m / FCF TTM 291.2m)
Total Stockholder Equity = 848.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.99% (Net Income 96.3m / Total Assets 2.37b)
RoE = 11.35% (Net Income TTM 96.3m / Total Stockholder Equity 848.5m)
RoCE = 7.49% (EBIT 151.1m / Capital Employed (Equity 848.5m + L.T.Debt 1.17b))
RoIC = 5.47% (NOPAT 111.6m / Invested Capital 2.04b)
WACC = 5.61% (E(4.76b)/V(5.94b) * Re(6.53%) + D(1.18b)/V(5.94b) * Rd(2.59%) * (1-Tc(0.26)))
Discount Rate = 6.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.42 | Cagr: -5.09%
[DCF] Terminal Value 77.97% ; FCFF base≈250.4m ; Y1≈287.0m ; Y5≈422.4m
[DCF] Fair Price = 118.7 (EV 6.36b - Net Debt 958.0m = Equity 5.40b / Shares 45.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.36 | EPS CAGR: 12.91% | SUE: 1.38 | # QB: 1
Revenue Correlation: 58.11 | Revenue CAGR: 1.95% | SUE: 1.54 | # QB: 2
EPS current Quarter (2026-09-30): EPS=1.29 | Chg30d=+0.08% | Revisions=+25% | Analysts=11
EPS next Quarter (2026-12-31): EPS=1.36 | Chg30d=+0.31% | Revisions=+25% | Analysts=11
EPS current Year (2027-03-31): EPS=5.31 | Chg30d=+0.22% | Revisions=+79% | GrowthEPS=+7.0% | GrowthRev=+6.2%
EPS next Year (2028-03-31): EPS=5.78 | Chg30d=+0.65% | Revisions=+25% | GrowthEPS=+8.8% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: +64% (up=19, down=3)